Literature DB >> 25323413

Economic evaluations of implantable cardioverter defibrillators: a systematic review.

Lidia García-Pérez1,2,3,4, Pilar Pinilla-Domínguez5,6, Antonio García-Quintana7, Eduardo Caballero-Dorta7, F Javier García-García8, Renata Linertová5,9,10,11, Iñaki Imaz-Iglesia10,12.   

Abstract

The aim of this paper was to review the cost-effectiveness studies of implantable cardioverter defibrillators (ICD) for primary or secondary prevention of sudden cardiac death (SCD). A systematic review of the literature published in English or Spanish was performed by electronically searching MEDLINE and MEDLINE in process, EMBASE, NHS-EED, and EconLit. Some keywords were implantable cardioverter defibrillator, heart failure, heart arrest, myocardial infarction, arrhythmias, syncope, sudden death. Selection criteria were the following: (1) full economic evaluations published after 1995, model-based studies or alongside clinical trials (2) that explored the cost-effectiveness of ICD with or without associated treatment compared with placebo or best medical treatment, (3) in adult patients for primary or secondary prevention of SCD because of ventricular arrhythmias. Studies that fulfilled these criteria were reviewed and data were extracted by two reviewers. The methodological quality of the studies was assessed and a narrative synthesis was prepared. In total, 24 studies were included: seven studies on secondary prevention and 18 studies on primary prevention. Seven studies were performed in Europe. For secondary prevention, the results showed that the ICD is considered cost-effective in patients with more risk. For primary prevention, the cost-effectiveness of ICD has been widely studied, but uncertainty about its cost-effectiveness remains. The cost-effectiveness ratios vary between studies depending on the patient characteristics, methodology, perspective, and national settings. Among the European studies, the conclusions are varied, where the ICD is considered cost-effective or not dependent on the study.

Entities:  

Keywords:  Cost-effectiveness; Heart failure; Implantable cardioverter defibrillator; Prevention; Sudden cardiac death; Systematic review

Mesh:

Year:  2014        PMID: 25323413     DOI: 10.1007/s10198-014-0637-x

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  52 in total

1.  Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.

Authors:  Kristian B Filion; Xuanqian Xie; Charlotte J van der Avoort; Nandini Dendukuri; James M Brophy
Journal:  Int J Technol Assess Health Care       Date:  2009-03-31       Impact factor: 2.188

2.  Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverter-defibrillator therapy in Belgium.

Authors:  Hans Van Brabandt; Mattias Neyt
Journal:  Europace       Date:  2009-10-08       Impact factor: 5.214

Review 3.  Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis.

Authors:  Melissa H Kong; Sana M Al-Khatib; Gillian D Sanders; Vic Hasselblad; Eric D Peterson
Journal:  Cardiol J       Date:  2011       Impact factor: 2.737

4.  Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II).

Authors:  Afschin Gandjour; Astrid Holler; Charles Christian Adarkwah
Journal:  Value Health       Date:  2011 Sep-Oct       Impact factor: 5.725

5.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

6.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; D Roy; R S Sheldon; L B Mitchell; M S Green; G J Klein; B O'Brien
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

7.  Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study.

Authors:  R Sheldon; B J O'Brien; G Blackhouse; R Goeree; B Mitchell; G Klein; R S Roberts; M Gent; S J Connolly
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

8.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT.

Authors:  S Adam Strickberger; John D Hummel; Thomas G Bartlett; Howard I Frumin; Claudio D Schuger; Scott L Beau; Cynthia Bitar; Fred Morady
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

9.  Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.

Authors:  Giuseppe Boriani; Frieder Braunschweig; Jean Claude Deharo; Francisco Leyva; Andrzej Lubinski; Carlo Lazzaro
Journal:  Europace       Date:  2013-05-21       Impact factor: 5.214

Review 10.  Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence.

Authors:  Larry D Lynd; Bernie J O'Brien
Journal:  J Cardiovasc Electrophysiol       Date:  2003-09
View more
  3 in total

Review 1.  Economic Issues in Heart Failure in the United States.

Authors:  Paul A Heidenreich; Gregg C Fonarow; Yekaterina Opsha; Alexander T Sandhu; Nancy K Sweitzer; Haider J Warraich
Journal:  J Card Fail       Date:  2022-01-24       Impact factor: 6.592

2.  No Association Between T-peak to T-end Interval on the Resting ECG and Long-Term Incidence of Ventricular Arrhythmias Triggering ICD Interventions.

Authors:  Peter Michalek; Sasha Benjamin Hatahet; Martin Svetlosak; Peter Margitfalvi; Iveta Waczulikova; Sebastian Trnovec; Allan Böhm; Ondrej Benacka; Robert Hatala
Journal:  Front Physiol       Date:  2020-08-31       Impact factor: 4.566

Review 3.  Economic benefits of microprocessor controlled prosthetic knees: a modeling study.

Authors:  Christine Chen; Mark Hanson; Ritika Chaturvedi; Soeren Mattke; Richard Hillestad; Harry H Liu
Journal:  J Neuroeng Rehabil       Date:  2018-09-05       Impact factor: 4.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.